194669-45-9

Usage

Functional Groups

Ester, Flavonoid, Short-chain fatty acid

Structure

The molecule consists of a pyridine ring with a carboxylic acid group, a 3-methoxyphenyl group, and a 1,1-dimethylethyl ester group.

Esterification

The esterification of naringenin (a flavonoid) with butyric acid (a short-chain fatty acid) forms Naringenin-7-butyrate.

Source

Naringenin is found in citrus fruits.

Health Benefits

Potential anti-inflammatory and antioxidant properties, supporting gut health, and promoting a healthy inflammatory response.

Bioavailability

Esterification with butyric acid may enhance the bioavailability of naringenin.

Therapeutic Effects

The compound may have potential therapeutic effects due to the combination of naringenin and butyric acid.

Research Interest

The compound is of interest for further research and development in the field of health and medicine.

Upstream product

• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 766-85-8 3-methoxy-1-iodobenzene 
• 2398-37-0 3-methoxyphenyl bromide 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 871112-35-5 tert-butyl 4-hydroxy-4-(3-methoxyphenyl)piperidine-1-carboxylate 
• 10365-98-7 3-methoxyphenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1276045-01-2 2-ethyl-1-[4-(3-methoxy-phenyl)-piperidin-1-yl]-butan-1-one 
• 1276045-02-3 1-(4-(3-methoxyphenyl)piperidin-1-yl)-3-methylbutan-1-one 
• 1276045-03-4 cyclopropyl-[4-(3-methoxy-phenyl)-piperidin-1-yl]-methanone 
• 1276045-04-5 [4-(3-methoxy-phenyl)-piperidin-1-yl]-(2-methyl-cyclopropyl)-methanone 
• 1276045-05-6 (2,2-dimethyl-cyclopropyl)-[4-(3-methoxy-phenyl)-piperidin-1-yl]-methanone 
• 1276045-06-7 cyclobutyl(4-(3-methoxyphenyl)piperidin-1-yl)methanone 
• 1276045-07-8 cyclopentyl(4-(3-methoxyphenyl)piperidin-1-yl)methanone 
• 1276045-08-9 cyclohexyl(4-(3-methoxyphenyl)piperidin-1-yl)methanone 
• 1276045-09-0 [4-(3-methoxy-phenyl)-piperidin-1-yl]-phenyl-methanone 
• 1276045-10-3 cyclopropyl-[4-(3-ethoxy-phenyl)-piperidin-1-yl]-methanone 
• 1276045-12-5 cyclopropyl-[4-(3-hydroxy-phenyl)-piperidin-1-yl]-methanone 
• 1276045-17-0 C₁₄H₁₉NO₃ 
• 1307314-95-9 4-(3-methoxy-phenyl)-piperidine trifluoroacetate 
• 1276044-98-4 1-[4-(3-methoxy-phenyl)-piperidin-1-yl]-ethanone 

Relevant academic research and scientific papers

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

PYRROLOTRIAZINES AS ALK INHIBITORS

This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.

Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl- cyclopropane carboxamide derivatives as novel melatonin receptor ligands

Two series of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives exhibiting diverse functionality at rat MT1 and MT2 receptors are reported. Compounds 11f and 18b (MT 1/MT2 agonist) have human microsomal intrinsic clearance comparable to ramelteon.

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists

This report describes replacement of the 4-(4-fluorophenyl)piperidine moiety in our CCR2 antagonists with 4-heteroaryl piperidine and 4-(carboxyphenyl)-piperidine subunits. Some of the resulting analogs retained potency in our CCR2 binding assay and had i

Synthesis of 4-substituted tetrahydropyridines by cross-coupling of enol phosphates

Enol phosphates, synthesized from 4-piperidone, react by palladium catalyzed cross-coupling with arylboronic acids and by iron and palladium catalyzed cross-coupling with Grignard reagents to give 4-substituted tetrahydropyridines.

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic